IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors

Autor: Yu Wang, Shunsuke Shimosaki, Emi Ikebe, Hidekatsu Iha, Jun-ichi Yamamoto, Nichole Fife, Tomonaga Ichikawa, Mitsuo Hori, Masao Ogata, Yoshiyuki Tsukamoto, Naoki Hijiya, Masatsugu Moriyama, Shotaro Hagiwara, Shuichi Kusano, Masumichi Saito, Kamruddin Ahmed, Akira Nishizono, Hiroshi Handa, Kazuhiro Morishita

Publikováno v: Frontiers in Oncology, Vol 13 (2024)

Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell neoplasia associated with human T-cell leukemia virus type 1 (HTLV-1) infection and has an extremely poor prognosis. Lenalidomide (LEN; a second-generation immunomodulatory drug [IMiD]) has

Externí odkaz: https://doaj.org/article/c652ad6387c14272840172d06da6e59c

A Phase I, Open-Label, Mass Balance Study of [¹⁴C]-Iberdomide in Healthy Subjects.

Autor: Cheng, Yiming, Wang, Xiaomin, Liu, Liangang, Silva, Jose, Thomas, Michael, Li, Yan

Publikováno v: European Journal of Drug Metabolism & Pharmacokinetics; May2024, Vol. 49 Issue 3, p355-365, 11p

A Phase I, Open-Label, Mass Balance Study of [14C]-Iberdomide in Healthy Subjects

Autor: Cheng, Yiming, Wang, Xiaomin, Liu, Liangang, Silva, Jose, Thomas, Michael, Li, Yan

Publikováno v: European Journal of Drug Metabolism and Pharmacokinetics; May 2024, Vol. 49 Issue: 3 p355-365, 11p

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors.

Autor: Wang Y; Department of Microbiology, Faculty of Medicine, Oita University, Yufu, Japan., Shimosaki S; Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan., Ikebe E; Department of Microbiology, Faculty of Medicine, Oita University, Yufu, Japan.; Research Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, Musashi-murayama, Japan., Iha H; Department of Microbiology, Faculty of Medicine, Oita University, Yufu, Japan.; Division of Pathophysiology, The Research Center for GLOBAL and LOCAL Infectious Diseases (RCGLID), Oita University, Yufu, Japan.; Borneo Medical and Health Research Centre, Faculty of Medicine and Health Sciences, University of Malaysia Sabah, Kota Kinabalu, Malaysia., Yamamoto JI; Department of Nanoparticle Translational Research, Tokyo Medical University, Tokyo, Japan., Fife N; Department of Microbiology, Faculty of Medicine, Oita University, Yufu, Japan., Ichikawa T; Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan., Hori M; Department of Hematology, Ibaraki Prefectural Central Hospital, Kasama, Japan., Ogata M; Division of Pathophysiology, The Research Center for GLOBAL and LOCAL Infectious Diseases (RCGLID), Oita University, Yufu, Japan.; Department of Hematology and Oncology, Faculty of Medicine, Oita University, Yufu, Japan., Tsukamoto Y; Department of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan., Hijiya N; Department of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan., Moriyama M; Department of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan., Hagiwara S; Mito Center for Regional Medical Education, University of Tsukuba, Ibaraki, Japan., Kusano S; Division of Biological Information Technology, Joint Research Center for Human Retrovirus Infection, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan., Saito M; Research Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, Musashi-murayama, Japan., Ahmed K; Borneo Medical and Health Research Centre, Faculty of Medicine and Health Sciences, University of Malaysia Sabah, Kota Kinabalu, Malaysia., Nishizono A; Department of Microbiology, Faculty of Medicine, Oita University, Yufu, Japan.; Division of Pathophysiology, The Research Center for GLOBAL and LOCAL Infectious Diseases (RCGLID), Oita University, Yufu, Japan., Handa H; Department of Nanoparticle Translational Research, Tokyo Medical University, Tokyo, Japan., Morishita K; Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Publikováno v: Frontiers in oncology [Front Oncol] 2024 Jan 24; Vol. 13, pp. 1272528. Date of Electronic Publication: 2024 Jan 24 (Print Publication: 2023).

A Phase I, Open-Label, Mass Balance Study of [ ¹⁴ C]-Iberdomide in Healthy Subjects.

Autor: Cheng Y; Clinical Pharmacology, Pharmacometrics, Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA., Wang X; Clinical Pharmacology, Pharmacometrics, Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA., Liu L; Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ, USA., Silva J; Clinical Pharmacology, Pharmacometrics, Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA., Thomas M; Clinical Scientist Early Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA., Li Y; Clinical Pharmacology, Pharmacometrics, Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA. Yan.Li@bms.com.; Clinical Pharmacology, Pharmacometrics, Disposition and Bioanalysis, Bristol Myers Squibb, 556 Morris Ave, Summit, NJ, 07901, USA. Yan.Li@bms.com.

Publikováno v: European journal of drug metabolism and pharmacokinetics [Eur J Drug Metab Pharmacokinet] 2024 May; Vol. 49 (3), pp. 355-365. Date of Electronic Publication: 2024 Mar 23.